Written by the Nuvirox Research Team
Key points
- Insomnia is one of the most common early side effects of SSRIs and SNRIs -- trial data puts the average rate around 17%, compared to roughly 8% on placebo.
- Risk varies a lot by drug: reboxetine, vilazodone, and desvenlafaxine carry the highest reported odds; some antidepressants (like escitalopram) tend to be gentler on sleep.
- This isn't a supplement problem to self-treat around -- it's a conversation for your prescriber, especially because Sleep+ Restore contains ingredients that can interact with SSRIs.
Short answer: it's a real, common, dose-related side effect -- and there's a right and a wrong way to handle it. If you started an SSRI or SNRI in the last few weeks and your sleep fell apart, you're not imagining a connection and you're not alone. Across 216 randomized trials covering nearly 65,000 patients, antidepressants as a class showed measurably higher rates of treatment-emergent insomnia than placebo (Zhou S, Li P, Lv X, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46(10):zsad177. doi:10.1093/sleep/zsad177. PMID: 37440602 (PMC10566234)). What's less well known is that the risk isn't uniform -- it depends heavily on which drug you're on, and there are legitimate, non-supplement ways to manage it while you and your prescriber figure out the right long-term plan.
Why would an antidepressant cause insomnia in the first place?
SSRIs and SNRIs increase synaptic serotonin, and serotonin signaling interacts directly with sleep architecture -- particularly REM sleep. Several of these drugs delay REM onset, increase nighttime awakenings, and reduce slow-wave sleep, especially in the first few weeks of treatment before the nervous system adapts. Some antidepressants are also mildly activating during the day, which can bleed into difficulty winding down at night if taken later in the day.
How common is this, really?
The most comprehensive answer comes from a 2023 network meta-analysis in the journal Sleep, which pooled data from 216 double-blind randomized trials (Zhou S, Li P, Lv X, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46(10):zsad177. doi:10.1093/sleep/zsad177. PMID: 37440602 (PMC10566234)). It found that, compared with placebo, 11 of the antidepressants studied showed significantly higher odds of insomnia. Reboxetine ranked highest (odds ratio 3.47), with vilazodone and desvenlafaxine close behind. On the other end, amitriptyline was actually associated with lower insomnia risk than placebo -- though it carries its own side-effect profile that usually rules it out as a simple swap. Separately, older FDA trial-registry data put the average treatment-emergent insomnia rate for SSRIs at roughly 17%, against about 8% for placebo.
What human studies actually show
The 2023 Sleep network meta-analysis is the largest and most rigorous dataset available. Across 64,696 patients in 216 trials, it modeled dose-response curves for both insomnia and somnolence and found the relationship wasn't always linear (Zhou S, Li P, Lv X, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46(10):zsad177. doi:10.1093/sleep/zsad177. PMID: 37440602 (PMC10566234)) -- for some drugs, insomnia risk rose steadily with dose; for others, it plateaued or even reversed at higher doses, likely reflecting sedating secondary effects that kick in at higher exposure.
An earlier review in the journal Sleep (Wichniak et al., cited widely in this literature) found that fluoxetine specifically delays REM onset and reduces total sleep time and sleep efficiency in polysomnography studies -- a mechanistic explanation for why some people feel their sleep is measurably lighter and more fragmented, not just subjectively worse.
The honest counterweight: not every antidepressant increases insomnia risk, and for some patients the opposite is true -- sedating antidepressants like mirtazapine and trazodone are, if anything, associated with excessive daytime sleepiness rather than insomnia. This means "antidepressants disrupt sleep" is too broad a claim; the real story is drug-specific, and switching within the same class can sometimes resolve the problem without switching away from treatment entirely.
What this doesn't mean
New insomnia after starting a psychiatric medication is not a sign you should stop taking it on your own. Depression and anxiety disorders themselves cause insomnia -- often worse than the medication does -- and abruptly stopping an SSRI or SNRI can trigger its own withdrawal syndrome (we cover that separately in our piece on stopping antidepressants). If your sleep hasn't settled after 4-6 weeks, or it's severe enough to affect your daytime functioning, that's a reason to call your prescriber -- not a reason to quit cold turkey or to layer supplements on top without checking for interactions.
What actually helps in the meantime
A few evidence-supported, low-risk options to raise with your prescriber: taking the medication in the morning rather than at night if it's one of the more activating ones; asking whether a dose adjustment or a switch within the same class is reasonable; and using standard sleep-hygiene measures (consistent wake time, morning light, no screens in bed) that we detail in how to sleep better naturally. Cognitive behavioral therapy for insomnia (CBT-I) is also well-supported as an add-on for medication-related sleep disruption and doesn't carry interaction risk.
Frequently asked questions
Will this insomnia go away on its own?
For many people, yes -- sleep-related side effects often ease within the first few weeks as the body adjusts. If it hasn't improved after about a month, or it's significantly affecting your daytime function, that's worth flagging to your prescriber rather than waiting it out indefinitely.
Is it safe to take melatonin or an herbal sleep aid alongside my antidepressant?
Not automatically. Some sleep-support ingredients -- including St. John's Wort and 5-HTP, both found in melatonin-plus-herbal formulas -- can interact with SSRIs and SNRIs, in some cases raising serotonin syndrome risk. Any addition should be reviewed with your prescriber or pharmacist first.
Does switching antidepressants usually fix the sleep problem?
Sometimes. Because insomnia risk varies significantly by specific drug (not just by class), a switch to a lower-risk option -- or a dose or timing adjustment -- can resolve it for some patients. This is a decision for your prescriber, based on your full clinical picture, not a self-directed swap.
Could it actually be my depression or anxiety causing the insomnia, not the drug?
It's genuinely hard to separate the two in the first few weeks, since untreated depression and anxiety are themselves major causes of insomnia. This is one of the reasons abrupt self-discontinuation is discouraged -- it can make sleep worse on both fronts at once.
A note before you consider a supplement
Sleep+ Restore contains 5-HTP and St. John's Wort, both of which can interact with SSRIs and SNRIs -- including a risk of serotonin syndrome with 5-HTP combined with serotonergic antidepressants. If insomnia started after a new antidepressant, the right next step is a conversation with your prescribing clinician or pharmacist about the medication itself, not a supplement layered on top of it.
The bottom line
Insomnia after starting an SSRI or SNRI is common, well-documented, and usually manageable -- but the right first move is a conversation with the person who prescribed the medication, not a self-directed workaround. The trial data shows real differences between drugs, which means there's often a path to better sleep that doesn't require abandoning treatment.
References
- Zhou S, Li P, Lv X, et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023;46(10):zsad177. doi:10.1093/sleep/zsad177. PMID: 37440602 (PMC10566234)
- Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526-535. doi:10.1016/S2215-0366(24)00133-0.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.